阿那白滞素、沙利鲁单抗、司妥昔单抗和托珠单抗治疗COVID-19的系统综述与荟萃分析
在前瞻性研究中,托珠单抗与未调整生存改善相关(风险比0.83,95%CI 0.72-0.96),但其他结局未显示确切获益;其他药物证据不足。
要点
- 托珠单抗在前瞻性研究中与较低死亡风险相关,但其他结局获益不确定。
- 阿那白滞素、司妥昔单抗或沙利鲁单抗治疗COVID-19的证据不足。
- 回顾性研究异质性大,结果需谨慎解读。
核心结论
- 托珠单抗在前瞻性研究中与较低相对死亡风险相关,但其他结局效果不确定。
- 阿那白滞素、司妥昔单抗或沙利鲁单抗治疗COVID-19的疗效证据不足,需进一步研究。
研究设计与样本
- 系统综述与荟萃分析,检索截至2021年1月7日的电子数据库。
- 大多数研究(60/71)探讨托珠单抗的结局。
主要发现
- 前瞻性研究中,托珠单抗与未调整生存改善相关(风险比0.83,95%CI 0.72-0.96,I2=0.0%)。
- 回顾性研究中,托珠单抗与较轻的序贯量表结局相关(广义OR 1.34,95%CI 1.10-1.64,I2=98%)。
- 回顾性研究中,托珠单抗与调整后死亡风险降低相关(HR 0.52,95%CI 0.41-0.66,I2=76.6%)。
- 住院时间平均差异为0.36天(95%CI -0.07至0.80,I2=93.8%)。
- 其他免疫调节剂显示与托珠单抗相似的效果,但数据不足无法按药物进行荟萃分析。
关键数值与推荐
- 主要结局为干预后第15天序贯量表严重程度和住院至出院时间。
- 关键次要终点包括总死亡率。
临床怎么用
- 托珠单抗可能降低COVID-19患者死亡风险,但需结合其他结局谨慎使用。
- 其他白介素抑制剂在COVID-19中的应用尚缺乏充分证据支持。
局限性
- 回顾性研究存在显著异质性,估计值应谨慎解读。
- 其他免疫调节剂数据不足,无法进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review and meta-analysis, we assess the effectiveness of specific interleukin inhibitors for the treatment of COVID-19. METHODS: Electronic databases were searched on 7 January 2021 to identify studies of immunomodulatory agents (anakinra, sarilumab, siltuximab and tocilizumab) for the treatment of COVID-19. The primary outcomes were severity on an Ordinal Scale measured at day 15 from intervention and days to hospital discharge. Key secondary endpoints included overall mortality. RESULTS: 71 studies totalling 22 058 patients were included, 6 were randomised trials. Most studies explored outcomes in patients who received tocilizumab (60/71). In prospective studies, tocilizumab was associated with improved unadjusted survival (risk ratio 0.83, 95% CI 0.72 to 0.96, I2=0.0%), but conclusive benefit was not demonstrated for other outcomes. In retrospective studies, tocilizumab was associated with less severe outcomes on an Ordinal Scale (generalised OR 1.34, 95% CI 1.10 to 1.64, I2=98%) and adjusted mortality risk (HR 0.52, 95% CI 0.41 to 0.66, I2=76.6%). The mean difference in duration of hospitalisation was 0.36 days (95% CI -0.07 to 0.80, I2=93.8%). There was substantial heterogeneity in retrospective studies, and estimates should be interpreted cautiously. Other immunomodulatory agents showed similar effects to tocilizumab, but insufficient data precluded meta-analysis by agent. CONCLUSION: Tocilizumab was associated with a lower relative risk of mortality in prospective studies, but effects were inconclusive for other outcomes. Current evidence for the efficacy of anakinra, siltuximab or sarilumab in COVID-19 is insufficient, with further studies urgently needed for conclusive findings. PROSPERO REGISTRATION NUMBER: CRD42020176375.
引用
- Khan FA, Stewart I, Fabbri L, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax. 2021. PMID: 33579777. doi:10.1136/thoraxjnl-2020-215266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。